THE EXPERIMENTAL SUBSTANTIATION OF ADVISABILITY OF INTRODUCING AN ADJUVANT TO THE COMPOSITION OF THE IMMUNOBIOLOGICAL SOLUTION “CANDIDOCYDE”

M.V. Rybalkin, N.I. Filimonova
National University of Pharmacy

Key words: candidiasis; antigen; vaccine; immunity; adjuvant

Candidal disease is growing around the world, and it is associated with a wide administration of antimicrobial, hormonal medicines and cytostatic drugs. To fight candidal infections the studies in developing vaccines against candidiasis are carried out actively in recent years in the world. At the premises of the National University of Pharmacy at the Biotechnology Department and the Department of Microbiology, Virology and Immunology the authors have developed a potential vaccine – the immunobiological solution “Candidocyde” based on the associated antigens of C. albicans and C. tropicalis fungi obtained by using ultrasound. For the purpose of the experimental substantiation of advisability of introducing an adjuvant to the composition of the immunobiological solution “Candidocyde” developed for preventing and treating candidal infections and based on the antigens of C. albicans and C. tropicalis fungi with the protein concentration of 3 mg/ml the samples of the solution “Candidocyde” separately with aluminium hydroxide and aluminium phosphate as adjuvants have been prepared and studied. The studies were performed in white mice with six animals in the group. The experimental samples in the volume of 0.2 ml were injected intramuscularly twice with the interval of 14 days. According to the results of the research conducted it has been found that the immunobiological solution “Candidocyde” based on the antigens of C. albicans and C. tropicalis fungi with the protein concentration of 3 mg/ml and the adjuvant under study with two intramuscular injections in the volume of 0.2 ml does not provide efficiency increase when preventing and treating candidal infections. Therefore, the adjuvant introduction into the composition of the immunobiological solution “Candidocyde” is impractical.

To fight candidal infections the studies in developing vaccines against candidiasis are carried out actively in recent years both in the CIS countries, and in the countries of Europe and America [8, 10]. It should be noted that currently no domestic vaccine is produced in Ukraine and no imported vaccines for prevention and treatment of candidiasis have been registered. Therefore, development of a vaccine against candidal infection is the topical issue of modern pharmacy and medicine.

Taking into account the aforementioned, as well as the modern tendencies of combined subunit vaccines development [3, 6] it is expedient to create vaccines for preventing and treating candidal infections based on C. albicans and C. tropicalis fungi.

At the premises of the National University of Pharmacy at the Biotechnology Department and the Department of Microbiology, Virology and Immunology the authors have developed a potential vaccine – the immunobiological solution “Candidocyde” based on the associated antigens of C. albicans and C. tropicalis fungi obtained by using ultrasound.

Most vaccines cause a suboptimal immunological response. Intensification of immunogenic response to the vaccine introduction is possible due to addition of different substances or adjuvants to the vaccine, they can increase the vaccine activity, namely stimulate the antibody synthesis and inhibit the absorption of antigens [1].

Vaccines can be adsorbed on aluminium hydroxide, aluminium phosphate, calcium phosphate or other similar adsorbents prepared under special conditions that provide the appropriate physical state and adsorption properties [1, 5, 9].

Stability of each adjuvant individually or in combination with antigen/antigens, especially for critical parameters, is determined in the process of development [4, 7]. It should be noted that there are a lot of investigations concerning the harmful effects of these adjuvants on the human body [11-14]. That is why before introducing an adjuvant into the composition of vaccines it is necessary to verify that the effect obtained will be sufficiently significant.

The immunobiological solution “Candidocyde” developed contains the antigens of C. albicans fungi with the protein concentration of 3 mg/ml and C. tropicalis fungi with the protein concentration of 5 mg/ml in the ratio of 1:1, i.e.
The immunobiological solution with the concentration of 4 mg/ml was tested. Taking into account that the immunobiological solution proposed in the given protein concentration possesses 100% activity when preventing and treating candidiases, the aim of this work is to substantiate experimentally advisability of introducing an adjuvant to the composition of the diluted immunobiological solution with the concentration of 3 mg/ml.

The test results were considered according to the number of various manifestations of the disease and were estimated by the following scheme: (−) – absence of manifestations of the disease; a mild form of the disease (+) – unempt appearance, refusal to eat, the body weight loss, dishfunctions of the excretory organs; a moderate form of the disease (+ +) – adynamia, unkempt appearance, refusal to eat, the body weight loss, contractures of the neck muscles, paralysis of the limbs, dysfunctions of the excretory organs; an advanced form of the disease (+ + +) – adynamia, unkempt appearance, refusal to eat, the body weight loss, contractures of the neck muscles, paralysis of the limbs, dysfunctions of the excretory organs, when examining the mucous membranes of natural orifices, the signs of pathological processes, plating of fungi with faeces were revealed; an advanced form of the disease (+ + +) – adynamia, unkempt appearance, refusal to eat, the body weight loss, contractures of the neck muscles, paralysis of the limbs, convulsions, the lateral location of the body, dysfunctions of the excretory organs, during the autopsy when examining the mucous membranes of natural orifices, internal organs of the animals the signs of such pathological processes as microabscesses in the renal cortical layer, lungs, spleen, liver, etc., isolation of retrocultures of fungi from the animals’ organs were

<table>
<thead>
<tr>
<th>Drug</th>
<th>Experimental animals</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results in 1 month</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>− + − − − −</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>+ − − − + −</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>− − + + − −</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Experimental animals</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Results in 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>− + − − + −</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>− − + + − −</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>+ − − − + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note:
1) A – the immunobiological substance with aluminium hydroxide adjuvant; B – the immunobiological substance with aluminium phosphate adjuvant;
2) − = absence of the disease, + = a mild form of the disease, ++ = a moderate form of the disease, +++ = an advanced form of the disease;
3) n – is the number of animals in a group.
revealed. This method was developed by the authors.

The therapeutic efficiency of the immunobiological solution with different adjuvants was investigated similarly to the method described above; the only difference was that the animals were infected with a contagium at first, and in 5 days two injections were made according to the scheme described. After that in 14 days the animals were examined and the results were determined.

Results and Discussion

According to the results of the research conducted it has been found that sorption of the adjuvants and antigen studied occurs completely; the negative test on protein detection by the Lowry protein assay indicates it after completion of the process.

The immunobiological solution "Candidocyde" with aluminium phosphate as an adjuvant in one month after repeated injection protected against infection 67% of animals, in 3 months – 67% of animals. The immunobiological solution with aluminium hydroxide as an adjuvant in one month after repeated injection of the drug protected against infection 83% of animals, in 3 months – 67% of animals. The experimental animals showed the signs of a mild form of the disease: unkempt appearance, refusal to eat, the body weight loss, dysfunctions of the excretory organs. The immunobiological solution without adjuvants gives the therapeutic effect in 83% of mice (Table 2).

Taking into account that addition of adjuvants to the composition of the immunobiological solution "Candidocyde" has not provided efficiency increase when preventing and treating candidal infections, as well as considering the fact that the immunobiological solution without adjuvants contains fewer excipients, it is more expedient not to use adjuvants. This decision is also based on a large number of data about the pernicious influence of adjuvants on the human body. It should be also noted that during storage adsorbed vaccines form a precipitate at the bottom of the container, and it negatively affects the further use of the immunobiological drug.

CONCLUSIONS

According to the results of the research conducted it has been found that the immunobiological solution "Candidocyde" based on the antigens of \textit{C. albicans} and \textit{C. tropicalis} fungi with the protein concentration of 3 mg/ml and the adjuvant under study with two intramuscular injections in the volume of 0.2 ml does not provide efficiency increase when preventing and treating candidal infections. Therefore, the adjuvant introduction into the composition of the immunobiological solution "Candidocyde" is impractical.

REFERENCES


ЕКСПЕРИМЕНТАЛЬНЕ ОБГРУНТУВАННЯ ДОЩІЛЬНОСТІ ВВЕДЕННЯ АДЬЮВАНТУ ДО СКЛАДУ ІМУНОБІОЛОГІЧНОГО РОЗЧИНА «КАНДІДОЦІД»

М.В.Рыбалкин, Н.І.Філімонова
Національний фармацевтичний університет

Ключові слова: кандидамікоз; антиген; вакцина; імунітет; ад'ювант

Захворюваність на кандидоз зростає у всьому світі, і це пов’язують з широким використанням антибактеріальних препаратів, гормональних засобів, цитостатиків. Для боротьби з кандидозною інфекцією в останні роки активно ведуться дослідження в усьому світі з розробки вакцин проти кандидамікозів. Ученими на базі Національного фармацевтичного університету на кафедрі біотехнології та мікробіології, вірусології та імунології було розроблено потенційну вакцину – імунобіологічний розчин «Кандидоцид» на основі антигенів грибів C. albicans та C. tropicalis, одержаних при використанні ультразвуку. З метою експериментального обґрунтування доцільності введення ад'юванту до складу розробленого імунобіологічного розчину «Кандидоцид» для попередження та лікування кандидозної інфекції на основі антигенів грибів C. albicans та C. tropicalis, були виготовлені і досліджено зразки розчину «Кандидоцид» з концентрацією білка 3 мг/мл з ад'ювантами гідроксидом алюмінію та фосфатом алюмінію. Дослідження проводили на білих мишах по 6 тварин у групі. Опытные образцы вводили двукратно внутрішньом’язово по 0,2 мл с інтервалом 14 діб. У результаті проведених досліджень встановлено, що імунобіологічний розчин «Кандидоцид» на основі антигенів грибів C. albicans та C. tropicalis з концентрацією білка 3 мг/мл з досліджуваними ад'ювантами при двукратному внутрішньом’язовому введенні не забезпечує підвищення ефективності при попередженні та лікуванні кандидозної інфекції. Тому введення ад'юванту до складу імунобіологічного розчину «Кандидоцид» недоцільне.

Address for correspondence:
12, Melnikov str., Kharkiv, 61002, Ukraine.
Tel. (057) 706-47-87. E-mail: Ribalkin.Nikolay@mail.ru.
National University of Pharmacy

Received in 03.10.2014